19.79
0.11 (0.56%)
| Previous Close | 19.68 |
| Volume | 3,356,944 |
| Price / Earnings (Forward) | 140.57 |
| Price / Sales | 1.29 |
| Price / Book | 10.50 |
| 52 Weeks Range |
| Profit Margin | -18.71% |
| Operating Margin (TTM) | -14.71% |
| Diluted EPS (TTM) | -2.79 |
| Quarterly Revenue Growth (YOY) | 22.30% |
| Total Debt/Equity (MRQ) | 320.75% |
| Current Ratio (MRQ) | 2.30 |
| Operating Cash Flow (TTM) | 13.94 M |
| Levered Free Cash Flow (TTM) | 67.48 M |
| Return on Assets (TTM) | -6.17% |
| Return on Equity (TTM) | -92.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Tandem Diabetes Care, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | -0.8 |
| Price Volatility | -2.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Relative Valuation | NA |
| Financial Health | -0.8 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.69 |
Select this tab to load the latest available analysis.
|
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 0.95% |
| % Held by Institutions | 110.87% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |